Klaus Hoeffken

427 total citations
22 papers, 256 citations indexed

About

Klaus Hoeffken is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Klaus Hoeffken has authored 22 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Hematology. Recurrent topics in Klaus Hoeffken's work include Cancer Cells and Metastasis (6 papers), Cancer Genomics and Diagnostics (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Klaus Hoeffken is often cited by papers focused on Cancer Cells and Metastasis (6 papers), Cancer Genomics and Diagnostics (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Klaus Hoeffken collaborates with scholars based in Germany, Austria and Spain. Klaus Hoeffken's co-authors include Ludger Pientka, Bernd Roehrig, Ulrich Wedding, Barbara M. Richartz, Oumar Camara, Ingo B. Runnebaum, Katharina Pachmann, Friedhelm Kuethe, Hans R. Figulla and Herbert G. Sayer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Klaus Hoeffken

21 papers receiving 242 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klaus Hoeffken Germany	11	95	63	57	54	43	22	256
Samip Master United States	10	136 1.4×	56 0.9×	86 1.5×	56 1.0×	60 1.4×	56	325
Yasufumi Matsuda Japan	10	70 0.7×	26 0.4×	65 1.1×	60 1.1×	34 0.8×	27	259
Stacy Epstein United States	6	108 1.1×	37 0.6×	56 1.0×	75 1.4×	54 1.3×	10	444
Paula Bruniera Brazil	9	63 0.7×	35 0.6×	24 0.4×	133 2.5×	43 1.0×	24	295
José R. Borbolla‐Escoboza Mexico	12	109 1.1×	21 0.3×	46 0.8×	80 1.5×	72 1.7×	18	386
Josephine A. Taverna United States	9	64 0.7×	43 0.7×	20 0.4×	30 0.6×	54 1.3×	21	227
Ajoy Dias United States	9	57 0.6×	50 0.8×	71 1.2×	36 0.7×	11 0.3×	27	216
Vittorio Fregoni Italy	11	157 1.7×	103 1.6×	173 3.0×	52 1.0×	35 0.8×	23	383
Yi‐Bin Chen United States	9	172 1.8×	45 0.7×	56 1.0×	30 0.6×	126 2.9×	12	308
Jette Sønderskov Gørløv Denmark	10	92 1.0×	44 0.7×	35 0.6×	31 0.6×	92 2.1×	15	235

Countries citing papers authored by Klaus Hoeffken

Since Specialization

Citations

This map shows the geographic impact of Klaus Hoeffken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Hoeffken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Hoeffken more than expected).

Fields of papers citing papers by Klaus Hoeffken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Hoeffken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Hoeffken. The network helps show where Klaus Hoeffken may publish in the future.

Co-authorship network of co-authors of Klaus Hoeffken

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Hoeffken. A scholar is included among the top collaborators of Klaus Hoeffken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Hoeffken. Klaus Hoeffken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoeffken, Klaus, et al.. (2021). A note from the editors. Journal of Cancer Research and Clinical Oncology. 147(1). 1–1. 1 indexed citations

Pachmann, Katharina, Oumar Camara, C. Rabenstein, et al.. (2010). Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. Journal of Cancer Research and Clinical Oncology. 137(5). 821–828. 19 indexed citations

Herbrecht, Raoul, A.M. Liberati, Javier Loscertales, et al.. (2009). Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study. Lund University Publications (Lund University). 94. 355–355. 1 indexed citations

Camara, Oumar, et al.. (2009). Behaviour and metastatic potential of her2/neu positive and her2/neu negative circulating epithelial tumor cells (CETC) during adjuvant systemic therapy in breast cancer.. Cancer Research. 69(2_Supplement). 5030–5030. 1 indexed citations

Camara, Oumar, Cornelia Jörke, C. Rabenstein, et al.. (2008). Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. Journal of Cancer Research and Clinical Oncology. 135(4). 643–647. 10 indexed citations

Pachmann, Katharina, et al.. (2008). The impact of systemic chemotherapy on circulating epithelial tumor cells (CETC) in breast cancer. Journal of Clinical Oncology. 26(15_suppl). 11001–11001. 2 indexed citations

Hoeffken, Klaus, et al.. (2008). Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans—a case report. Oral and Maxillofacial Surgery. 12(4). 209–213. 21 indexed citations

Knauf, Wolfgang, Toshko Lissitchkov, Ali Aldaoud, et al.. (2008). Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.. Blood. 112(11). 2091–2091. 11 indexed citations

Dresemann, G., Mark Rosenthal, Klaus Hoeffken, et al.. (2007). Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) - An international open label randomised phase III study (ambrosia-study). Neuro-Oncology. 9(4). 2 indexed citations

10.

Herold, Michael, Antje Haas, Sabine Neser, et al.. (2007). Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma - 42 Months Follow Up Results of the OSHO 39 Study.. Blood. 110(11). 4474–4474.

11.

Herold, Michael, Antje Haas, Sabine Neser, et al.. (2006). Addition of Rituximab to First-Line MCP (Mitoxantrone, Chlorambucil, Prednisolone) Chemotherapy Prolongs Survival in Advanced Follicular Lymphoma - 4 Year Follow-Up Results of a Phase III Trial of the East German Study Group Hematology and Oncology (OSHO#39).. Blood. 108(11). 484–484. 10 indexed citations

12.

Roehrig, Bernd, Klaus Hoeffken, Ludger Pientka, & Ulrich Wedding. (2006). How many and which items of activities of daily living (ADL) and instrumental activities of daily living (IADL) are necessary for screening. Critical Reviews in Oncology/Hematology. 62(2). 164–171. 50 indexed citations

13.

Pachmann, Katharina, Oumar Camara, Robert Dengler, et al.. (2006). Circulating tumor cells: Tools for monitoring and targets for therapy. Journal of Clinical Oncology. 24(18_suppl). 617–617. 2 indexed citations

14.

Kuethe, Friedhelm, Barbara M. Richartz, Christoph Kasper, et al.. (2005). Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans. International Journal of Cardiology. 100(3). 485–491. 33 indexed citations

15.

Pachmann, Katharina, et al.. (2005). Quantitative monitoring of circulating epithelial cells for individual therapy control in lung and breast cancer during neoadjuvant treatment, surgery and adjuvant chemotherapy. Journal of Clinical Oncology. 23(16_suppl). 631–631. 2 indexed citations

16.

Hofmann, W.-K., Gerhard Heil, Stephanie A. Wiebe, et al.. (2004). Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Annals of Hematology. 83(8). 498–503. 44 indexed citations

17.

Kasper, Christoph, et al.. (2004). First Report of a Prospective Randomised Controlled Trial of Recombinant Human Erythropoietin after Allogeneic Blood Stem Cell Transplantation.. Blood. 104(11). 1833–1833. 1 indexed citations

18.

Baum, Richard P., et al.. (2002). F-18 FDG PET and its potential in therapeutic management and 3D-radiation treatment planning of non-small cell lung cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics. 54(2). 33–34. 2 indexed citations

19.

Hoeffken, Klaus, et al.. (1990). Original article: CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer — A Phase I study. Annals of Oncology. 1(6). 421–426. 14 indexed citations

20.

Lindemann, A., Klaus Hoeffken, Reinhold E. Schmidt, et al.. (1989). A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies. Cancer Treatment Reviews. 16. 53–57. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact